- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06319027
Identificación de hallazgos en escáneres cerebrales que podrían ayudar a hacer mejores predicciones sobre la progresión del cáncer de cerebro: el ensayo GABLE (GABLE)
Ensayo de entorno de aprendizaje de biomarcadores acelerados de glioblastoma de fase II (GABLE)
This phase II trial studies whether different imaging techniques can provide additional and more accurate information than the usual approach for assessing the activity of tumors in patients with newly diagnosed glioblastoma. The usual approach for this currently is magnetic resonance imaging (MRI). This study is trying to learn more about the meaning of changes in MRI scans after treatment, as while the appearance of some of these changes may reflect progressing tumor, some may be due the treatment. Dynamic susceptibility contrast (DSC)-MRIs, along with positron emission tomography (PET) and/or magnetic resonance (MR) spectroscopy, may help doctors tell which changes are a reflection of the treatment and which changes may be due to progressing tumor.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
PRIMARY OBJECTIVE:
I. For each biomarker (dynamic susceptibility contrast-enhanced MR Imaging, fluciclovine F18 [18F-fluciclovine] PET, MR spectroscopy), to evaluate whether the biomarker can stratify patients with newly diagnosed glioblastoma (GBM) that have progressive enhancement within 12 weeks post-radiation therapy (XRT) into risk groups based on overall survival.
SECONDARY OBJECTIVES:
I. To evaluate whether each biomarker (dynamic susceptibility contrast-enhanced MR Imaging, 18F-fluciclovine PET, MR spectroscopy) can predict final determination of pseudo-progression (PsP) versus (vs.) true progression on follow-up MR imaging as evaluated by a semi-automated central reading process and by institutional radiologist readings.
II. To evaluate whether a prediction model that incorporates multiple biomarkers can discriminate patients with progressive enhancement within 12 weeks post-XRT into high and low risk groups for overall survival.
III. To evaluate whether clinical and imaging biomarkers are predictive of overall and progression-free survival in patients who do not show progressive enhancement within 12 weeks post-XRT.
EXPLORATORY OBJECTIVE:
I. To determine how different methods of defining PsP vs. true progression on imaging relate to patient survival.
OUTLINE:
Patients receive a gadolinium-based contrast agent and undergo DSC-MRI scans at 4 and 8 weeks after completion of standard of care (SOC) radiation therapy. Patients with evidence of disease progression then undergo MR spectroscopy or receive fluciclovine F18 intravenously (IV) and undergo PET scan within 12 weeks of SOC radiation therapy completion.
After completion of study intervention, patients are followed up every 8 weeks for 1 year followed by every 12 weeks for 5 years.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35233
- Reclutamiento
- University of Alabama at Birmingham Cancer Center
-
Contacto:
- Site Public Contact
- Correo electrónico: gingerreeves@uabmc.edu
-
Investigador principal:
- Jonathan E. McConathy
-
-
California
-
Los Angeles, California, Estados Unidos, 90048
- Reclutamiento
- Cedars-Sinai Medical Center
-
Investigador principal:
- Jeremy D. Rudnick
-
Contacto:
- Site Public Contact
- Número de teléfono: 310-423-2133
- Correo electrónico: Cancer.trial.info@cshs.org
-
-
Florida
-
Jacksonville, Florida, Estados Unidos, 32207
- Reclutamiento
- Baptist MD Anderson Cancer Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 904-202-7468
-
Investigador principal:
- Robert Cavaliere
-
Tampa, Florida, Estados Unidos, 33612
- Reclutamiento
- Moffitt Cancer Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 800-679-0775
- Correo electrónico: ClinicalTrials@moffitt.org
-
Investigador principal:
- Joaquim Farinhas
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Reclutamiento
- Emory University Hospital/Winship Cancer Institute
-
Contacto:
- Site Public Contact
- Número de teléfono: 404-778-1868
-
Investigador principal:
- Hui-Kuo G. Shu
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48109
- Reclutamiento
- University of Michigan Rogel Cancer Center
-
Investigador principal:
- Michelle M. Kim
-
Contacto:
- Site Public Contact
- Número de teléfono: 800-865-1125
- Correo electrónico: CancerAnswerLine@med.umich.edu
-
-
North Carolina
-
Charlotte, North Carolina, Estados Unidos, 28203
- Suspendido
- Carolinas Medical Center/Levine Cancer Institute
-
Durham, North Carolina, Estados Unidos, 27710
- Reclutamiento
- Duke University Medical Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 888-275-3853
-
Investigador principal:
- Annick Desjardins
-
Winston-Salem, North Carolina, Estados Unidos, 27157
- Reclutamiento
- Wake Forest University Health Sciences
-
Contacto:
- Site Public Contact
- Número de teléfono: 336-713-6771
-
Investigador principal:
- Marc Benayoun
-
-
Rhode Island
-
Providence, Rhode Island, Estados Unidos, 02903
- Suspendido
- Rhode Island Hospital
-
-
West Virginia
-
Huntington, West Virginia, Estados Unidos, 25701
- Reclutamiento
- Edwards Comprehensive Cancer Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 304-399-6566
- Correo electrónico: Christina.Cole@chhi.org
-
Investigador principal:
- Toni O. Pacioles
-
Morgantown, West Virginia, Estados Unidos, 26506
- Reclutamiento
- West Virginia University Healthcare
-
Contacto:
- Site Public Contact
- Número de teléfono: 304-293-7374
- Correo electrónico: cancertrialsinfo@hsc.wvu.edu
-
Investigador principal:
- Sonikpreet Aulakh
-
-
Wisconsin
-
Madison, Wisconsin, Estados Unidos, 53792
- Reclutamiento
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Contacto:
- Site Public Contact
- Número de teléfono: 800-622-8922
- Correo electrónico: clinicaltrials@cancer.wisc.edu
-
Investigador principal:
- Michael Veronesi
-
Madison, Wisconsin, Estados Unidos, 53718
- Reclutamiento
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
-
Contacto:
- Site Public Contact
- Número de teléfono: 800-622-8922
- Correo electrónico: clinicaltrials@cancer.wisc.edu
-
Investigador principal:
- Michael Veronesi
-
Menomonee Falls, Wisconsin, Estados Unidos, 53051
- Reclutamiento
- Froedtert Menomonee Falls Hospital
-
Investigador principal:
- Jennifer M. Connelly
-
Contacto:
- Site Public Contact
- Número de teléfono: 262-257-5100
-
Milwaukee, Wisconsin, Estados Unidos, 53226
- Reclutamiento
- Medical College of Wisconsin
-
Investigador principal:
- Jennifer M. Connelly
-
Contacto:
- Site Public Contact
- Número de teléfono: 414-805-3666
-
Oak Creek, Wisconsin, Estados Unidos, 53154
- Reclutamiento
- Drexel Town Square Health Center
-
Investigador principal:
- Jennifer M. Connelly
-
Contacto:
- Site Public Contact
- Número de teléfono: 414-805-0505
-
West Bend, Wisconsin, Estados Unidos, 53095
- Reclutamiento
- Froedtert West Bend Hospital/Kraemer Cancer Center
-
Investigador principal:
- Jennifer M. Connelly
-
Contacto:
- Site Public Contact
- Número de teléfono: 414-805-0505
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Patient must be ≥ 18 years of age.
-
Patient must have a Karnofsky Performance Status ≥ 60%.
-
Patient must have newly diagnosed GBM (must be IDH wild type), with pathologic proof, based on World Health Organization (WHO) 2021 criteria.
-
Patient must be planning to receive standard-of-care treatment for newly diagnosed glioblastoma.
-
Patient must have completed an MRI prior to the diagnostic surgery for GBM and have images available for upload into Transfer of Images and Data (TRIAD).
-
Patient must have diagnostic surgery for GBM within 7 weeks prior to registration.
-
Patient must have O6-Methylguanine-DNA Methyltransferase (MGMT) methylation status ordered at time of registration.
-
Patient must have a post-operative (op) MRI completed within 3 weeks after diagnostic surgery for GBM and have images available for upload into TRIAD.
-
Patient must have no contraindications to MRI, including injection of gadolinium-based contrast agents, and demonstrated ability to tolerate MRI on pre-surgical imaging.
-
Patient must have no allergies to agents that may potentially be used for non-standard of care imaging (18F-fluciclovine, MR contrast).
-
Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the interventions being used.
- All patients of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy.
- A patient of childbearing potential is defined as anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
-
Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible.
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Diagnóstico
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Diagnostic (DSC-MRI, fluciclovine F18 PET, MR spectroscopy)
Patients receive a gadolinium-based contrast agent and undergo DSC-MRI scans at 4 and 8 weeks after completion of SOC radiation therapy. Patients with evidence of disease progression then undergo MR spectroscopy or receive fluciclovine F18 IV and undergo PET scan within 12 weeks of SOC radiation therapy completion. |
Undergo PET scan
Otros nombres:
Given IV
Otros nombres:
Undergo DSC-MRI
Otros nombres:
Receive gadolinium-based contrast agent
Otros nombres:
Undergo MR spectroscopy
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Overall survival (OS)
Periodo de tiempo: From biomarker collection to death due to any cause, assessed up to 6 years
|
Will use a two-sided log-rank test to compare the difference in OS between marker positive and marker negative participants using a significance level of 0.05. |
From biomarker collection to death due to any cause, assessed up to 6 years
|
|
Event free survival (EFS)
Periodo de tiempo: From biomarker collection until progression by Neurological Assessment in Neuro-Oncology (NANO) criteria or death, assessed up to 6 years
|
NANO progression is defined as a ≥ 2 level worsening from baseline or best level of function in at least one domain or worsening to the highest score within ≥1 domain that is felt to be related to underlying tumor progression and not attributable to a comorbid event or change in concurrent medication. Will be based on the conditional power of a two-sided log-rank test for EFS between marker positive and marker negative participants using a significance level of 0.05. |
From biomarker collection until progression by Neurological Assessment in Neuro-Oncology (NANO) criteria or death, assessed up to 6 years
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Supervivencia libre de progresión (SSP)
Periodo de tiempo: Desde cirugía hasta lo más temprano de progresión o muerte por cualquier causa, evaluado hasta 6 años
|
Desde cirugía hasta lo más temprano de progresión o muerte por cualquier causa, evaluado hasta 6 años
|
|
|
True disease progression and pseudo-progression (PsP)
Periodo de tiempo: Within 12 weeks post radiation therapy (XRT)
|
The T3 MRI will be used to determine whether progressive enhancement seen within 12 weeks post-XRT was true progression or PsP. |
Within 12 weeks post radiation therapy (XRT)
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Daniel P Barboriak, ECOG-ACRIN Cancer Research Group
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Neoplasias
- Neoplasias por tipo histológico
- Neoplasias Glandulares y Epiteliales
- Astrocitoma
- Glioma
- Neoplasias Neuroepiteliales
- Tumores neuroectodérmicos
- Neoplasias De Células Germinales Y Embrionarias
- Neoplasias De Tejido Nervioso
- Glioblastoma
- Técnicas de investigación
- Técnicas de química, analítica
- Análisis de espectro
- Espectroscopía de resonancia magnética
- fluciclovina F-18
Otros números de identificación del estudio
- EAF223
- U10CA180820 (Subvención/contrato del NIH de EE. UU.)
- EAF223 (Otro identificador: CTEP)
- NCI-2023-08557 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
- EAF223 (Otro identificador: ECOG-ACRIN Cancer Research Group)
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .